Skip to content

Hola Lenire: Tinnitus Device Now Available in Spain

Lenire device

Lenire is now available as a treatment option for people living with tinnitus in Spain. Neuromod Devices has reached a distribution agreement with TRUSBIN, a medical device distributor, who will partner with specialist healthcare professionals in the country to make the device available.

Tinnitus, commonly known as “ringing in the ears”, is a complex neurological condition resulting in the perception of sound without an external source. A recent study published in The Lancet about the prevalence of tinnitus estimated that 15.5% of Spain’s adult population experience some form of tinnitus during their lifetimei.

Through the agreement, TRUSBIN’s multidisciplinary team of clinicians and commercial executives has licence from Neuromod to distribute Lenire in Spain. Initially Lenire will be available in Barcelona with plans to expand availability of the device.

TRUSBIN have reached an agreement with the renowned Otorhinolaryngologist Dr Jordi Coromina of the Teknon Clinic in Barcelona to be the first clinician in Spain providing treatment with the device.

“I’m delighted that by working with TRUSBIN we can make Lenire available to people living with tinnitus in Spain. We consider Barcelona to be an ideal starting point due to its tradition in the medical field and its concentration of clinical expertise and we’re looking forward to continually expanding the availability of Lenire throughout the country,” explains Dr Ross O’Neill, Founder and CEO of Neuromod Devices.

The agreement follows the publication of an independent real-world study demonstrating the safety and efficacy of the Lenire device for improving symptoms in tinnitus patients. The study found that 85% of tinnitus patients experienced a reduction in their tinnitus symptoms, as measured by THIii, following six to 12 weeks of treatment using Lenireiii. The results were recently published in the highly ranked scientific journal, Brain Stimulation.

Spain is the latest country that Lenire is available in following significant expansion of the device’s availability throughout Europe in 2021, including the UK, Switzerland, and Austria. Find out where Lenire is available using our clinical map.


(ii) THI or Tinnitus Handicap Inventory is a clinical standard for measuring the impact of tinnitus on someone’s day-to-day life. Measured on a scale of 100, the higher the score, the greater the impact of tinnitus. Reducing a person’s THI score should correspond to improved quality of life by reducing how their tinnitus is affecting them.

(iii) Buechner A, Lesinski-Schiedat A, Becker P, Lenarz T, Real-world clinical experience with bimodal neuromodulation for the treatment of tinnitus – A case series, Brain Stimulation (2022), doi:

Subscribe to our Newsletter

Our dedicated newsletter for healthcare professionals will keep you up to date with the Lenire® treatment and research.

In order to subscribe you to our newsletter, we require your consent to send marketing communications to you. Please tick the box below to consent to:

You can unsubscribe from these communications at any time. For more information view our privacy policy.

By clicking subscribe, you consent to allow Neuromod to store and process the personal information submitted above to provide you with the content requested.